Amicus Therapeutics (FOLD) – Management Comments
-
Amicus Therapeutics (FOLD) Reports Prelim FY23 Revenue, Provides 2024 Outlook
-
Amicus Therapeutics (FOLD) Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to FOLD Stock Lookup